Fig. 4

JNK-IN-8 cooperates with dasatinib in killing primary Ph⁺ B-ALL cells. a, c, e, g, i, and k Primary bone marrow cells isolated from 6 Ph⁺ B-ALL patients were treated with dasatinib (at the concentrations of 0, 0.125, 0.25, 0.5, 1, and 2 μmol/L), JNK-IN-8 (2.5, 5 μmol/L ) or both in combination for 48 h. Cell viability was measured by the CellTiter Glo assay. Data are presented as mean ± SD; P values were calculated by the comparison between the combination group and JNK-IN-8 or dasatinib alone group. *P < 0.05, **P < 0.01. b, d, f, h, j, and l CI values were calculated based on data from a, c, e, g, i, and k, respectively, and plotted. Fractional inhibition abbreviated as Fa